Fundamentals of Liver Disease - MASLD-MASLD For the Non-Hepatologist

Video Transcription

Video Summary

The session "MASLD for Non-Hepatologists," co-moderated by Dr. Vincent Chen and Dr. Sanal Kumar, explored various aspects of managing metabolic dysfunction-associated steatotic liver disease (MASLD) and related conditions. Dr. Viral Ajmera discussed risk stratification and referrals for MASLD, emphasizing the high prevalence of non-alcoholic fatty liver disease in the U.S. He highlighted the importance of identifying patients with fibrosis for treatment to prevent liver-related morbidity and mortality. Dr. Ajmera also reviewed several non-invasive tests and their accuracy in assessing liver fibrosis.<br /><br />Dr. Arpan Mohanty explained MET-ALD, a condition involving the coexistence of metabolic disease and alcohol consumption leading to liver disease. She stressed the need for this terminology to avoid false dichotomies in diagnosing liver conditions. Dr. Mohanty also discussed the complications of assessing alcohol intake and potential treatment options involving both metabolic treatments and addressing alcohol use disorder.<br /><br />Dr. Sujit Janardhan provided insights into treatments for MASLD and MAS, including pharmacotherapy and bariatric surgery. He discussed various medications like semaglutide, a glucagon-like peptide-1 agonist, and newly approved resmetarom as potential treatments. He also highlighted the significant benefits of bariatric surgery for patients with MASLD.<br /><br />The session concluded with a panel discussion on the roles of different healthcare providers in managing MASLD, the importance of collaboration among specialists, and ongoing research into new treatments. This comprehensive session underscored the need for tailored approaches to managing liver disease in patients with metabolic dysfunction.

Keywords

MASLD

Non-Hepatologists

Metabolic Dysfunction

Steatotic Liver Disease

Fibrosis

Non-Invasive Tests

MET-ALD

Alcohol Consumption

Pharmacotherapy

Bariatric Surgery

Semaglutide

Resmetarom